<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20150830023823N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-07-31</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Plantago major leaf gel on prevention of acute radiation dermatitis in breast cancer patients</public_title>
      <acronym></acronym>
      <scientific_title>Effect of Plantago major leaf gel compared to placebo on prevention of acute radiation dermatitis in breast cancer patients: A double blind, randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-08-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/56244</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Randomization method: we use permutation block randomization method with block size of 4. Selected samples based on these blocks are placed in treatment intervention (A) and placebo intervention (B) groups. All possible blocks are arranged as follows: block1:AABB, block 2:ABAB, block 3:ABBA, block 4:BBAA, block 5:BABA, block 6:BAAB.Therefore, according to the sample size (80 subjects) we need 20 blocks. For generation a list of 80 random sequences by permutation block method, we use Random allocation software    2.0. We randomly select these blocks from 1 to 6. Using Random allocation software 2.0, we choose a random number between the numbers 1 to 6. For example, if number 6 is selected as the first block and number 2 as the second block, BAABABAB will be the random sequences according to which people enter the study.We continue this to generate a list of 80 random sequences. Finally, based on this random list, 40 patients will be allocated to group A and 40 patients to group B, Blinding description: The placebo will be made in color, odor, package and other characteristics similar to plantago major gel so that the patients and the researchers can`t distinguish between them.</study_design>
      <phase>3</phase>
      <hc_freetext>Acute radio dermatitis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The drug of the intervention group is Plantago major leaf gel. This topical  skin gel is made by a pharmacist under the supervision of Shiraz School of Pharmacy.To prepare the topical form of the drug (gel), the  Plantago major leaf extract will be added to the gel stand.The gel will also be subjected to microbial control and chemical evaluation. Patients will be instructed to cover the skin of the area under radiation with a thin layer of topical gel twice a day (morning and night). The duration of use is 7 weeks that will continue from the first day of radiation therapy till 2 weeks after the last radiation therapy session. To reduce the effect of bolus, it is recommended that the minimum interval between the use of the gel and the start of each the radiation therapy session be two hours.Patients are also urged to avoid using other topical compounds during treatment. Intervention 2: Control group:placebo that will be applied by control group is the same gel stand used to preparing the plantago major gel. Placebo is also made by a pharmacist under the supervision of Shiraz School of Pharmacy. patients in this group will also be instructed to cover the skin of the area under radiation with a thin layer of topical gel(placebo) twice a day (morning and night). The duration of use is 7 weeks that will continue from the first day of radiation therapy till 2 weeks after the last radiation therapy session.It is also recommended for patients in this group that the minimum interval between the use of the gel and the start of each the radiation therapy session be two hours.Patients are also urged to avoid using other topical compounds during treatment.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is for privacy</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ali Tavakoli</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Zand St, Medical School, Seventh floor, Persian Medicine Department</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134845794</zip>
        <telephone>+98 71 3234 5145</telephone>
        <email>tavakkolia@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ali Tavakoli</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Zand St, Medical School, Seventh floor, Persian Medicine Department</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134845794</zip>
        <telephone>+98 71 3234 5145</telephone>
        <email>tavakkolia@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with definitive diagnosis of breast cancer who have undergone quadrantectomy treatment.
indication of external radiotherapy
18 years old and more</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>previous breast radiotherapy
skin tumor
rash, ulcer, scar
connective tissue disorder
diabetes melitus
concomitant use of chemotherapy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L58.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Acute radio dermatitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The drug of the intervention group is Plantago major leaf gel. This topical  skin gel is made by a pharmacist under the supervision of Shiraz School of Pharmacy.To prepare the topical form of the drug (gel), the  Plantago major leaf extract will be added to the gel stand.The gel will also be subjected to microbial control and chemical evaluation. Patients will be instructed to cover the skin of the area under radiation with a thin layer of topical gel twice a day (morning and night). The duration of use is 7 weeks that will continue from the first day of radiation therapy till 2 weeks after the last radiation therapy session. To reduce the effect of bolus, it is recommended that the minimum interval between the use of the gel and the start of each the radiation therapy session be two hours.Patients are also urged to avoid using other topical compounds during treatment.</i_keyword>
      <i_keyword>Control group:placebo that will be applied by control group is the same gel stand used to preparing the plantago major gel. Placebo is also made by a pharmacist under the supervision of Shiraz School of Pharmacy. patients in this group will also be instructed to cover the skin of the area under radiation with a thin layer of topical gel(placebo) twice a day (morning and night). The duration of use is 7 weeks that will continue from the first day of radiation therapy till 2 weeks after the last radiation therapy session.It is also recommended for patients in this group that the minimum interval between the use of the gel and the start of each the radiation therapy session be two hours.Patients are also urged to avoid using other topical compounds during treatment.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Dermatitis grade. Timepoint: weekly for 7 weeks. Method of measurement: observation by  physician with Common Terminology Criteria for Adverse Events(CTCAE) version 4.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Burning sensation grade. Timepoint: weekly. Method of measurement: Ask the patient with patient symptom scale.</sec_outcome>
      <sec_outcome>Pain. Timepoint: weekly. Method of measurement: Ask the patient with patient symptom scale.</sec_outcome>
      <sec_outcome>Pruritus. Timepoint: weekly. Method of measurement: Ask the patient with patient symptom scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-04-05</approval_date>
        <contact_name>Ethics Committee of Shiraz Medical School</contact_name>
        <contact_address>Zand St. Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
